Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 8/12/11, the week rolls out with volatility and confidence issues

The 6 W’s: Who, what, where, when, why and what of it…

Stocks posted gains early Friday, at the end of a choppy week of trading, as I “welcomed any positive announcements with a deep and cleansing breathe” a healthy report on retail sales. 

Markets in the EU were helped by the imposition of temporary bans on negative bets against financial stocks in 4 countries. Asian stocks had a lackluster trading day, the Euro Stoxx 50 index of euro zone blue chips was up 4% in afternoon trading and the FTSE 100 index in London was up 2.6%. The CAC 40 index in Paris was up 3.7%, and the DAX in Frankfurt 3.4%. In early trading, the S&P rose 1.2%. The Dow opened up 1.2% and the NASDAQ was up 0.7%. Investors remained on edge for any disturbing news on the European debt front, and for any signs that US economic growth is languishing or worsening.


The NASDAQ is now UP +27.63 (+1.11%) to 2, 520.31. The Dow is also UP +184.59 (+1.65%) to 11,327.90. Remembering, my old  fear component is the DOW is still UNDER 12,000.


Regenerative medicine/stem cell universe shares on 8/12/11 “are thankful its Friday as confidence is unbelievably low and the universe is very over-sold” After these few weeks of extreme volatility, we are all left with a decision … what do we do now … I elect to end the weekend early … And, wait until next week for an answer! The earnings finale will focus LPS’ (loss per share), viability and sustainability highlighting those companies needing cash … to stay … alive! 


Who is UP … Advanced Cell technology (ACTC.OB), Aastrom (ASTM), Athersys (NASDAQ:ATHX), Biotime (AMEX: BTX), Neuralstem (AMEX: CUR), NeoStem (AMEX: NBS), Opexa (OPXA), Osiris (NASDAQ:OSIR), ReNeuron (LSE: RENE.L) and Thermogenesis (NASDAQ:KOOL)


What’s new in the regenerative medicine/stem cell market … NOT MUCH … EARNINGS … still announcing

California institute opens center for RNAi research: The La Jolla Institute for Allergy & Immunology in California opened a center that will focus on RNA interference research. The bottom line, the RNAi Center just received a $12.6M grant from the NIH, aims to identify genes responsible for cancers, inflammation and other biological processes.